-
1.发明公开METHODS AND COMPOSITIONS USEFUL IN GENERATING NON CANONICAL CD8+ T CELL RESPONSES 审中-公开用于产生非典型CD8 + T细胞应答的方法和组合物
公开(公告)号：EP3256595A1
公开(公告)日：2017-12-20
申请号：EP16749813.8
申请日：2016-02-10
申请人： Oregon Health & Science University , Fruh, Klaus , Picker, Louis , Hansen, Scott , Sacha, Jonah
发明人： FRUEH, Klaus , PICKER, Louis , HANSEN, Scott , SACHA, Jonah , MALOULI, Daniel
IPC分类号： C12N15/86 , C12N15/12 , C12N15/33 , C07K14/705 , C07K14/725 , C12N5/0783 , C12Q1/68 , A61K48/00 , A61P35/00
CPC分类号： C12N15/86 , A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/53 , A61K2039/57 , C12N9/0093 , C12N15/00 , C12N2710/16143 , C12N2740/15034 , C12Q1/68 , Y02A50/412
摘要： Methods of inducing a CD8+ T cell response to a heterologous antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.
-
公开(公告)号：EP4017985A1
公开(公告)日：2022-06-29
申请号：EP20855077.2
申请日：2020-08-19
-
公开(公告)号：EP3473723A1
公开(公告)日：2019-04-24
申请号：EP18184904.3
申请日：2014-03-05
发明人： PICKER, Louis , HANSEN, Scott , FRUEH, Klaus , MALOULI, Daniel
摘要： Disclosed herein are CMV vectors that include a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL128 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL130 protein (or an ortholog thereof). Also disclosed herein are CMV vectors comprising: a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL130 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL128 protein. Further disclosed are methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II.
-
公开(公告)号：EP4036239A1
公开(公告)日：2022-08-03
申请号：EP21205026.4
申请日：2016-02-10
发明人： FRUEH, Klaus , PICKER, Louis , HANSEN, Scott , SACHA, Jonah , MALOULI, Daniel
IPC分类号： C12N15/86 , C12N15/12 , C12N15/33 , C07K14/705 , C07K14/725 , C12N5/0783 , C12Q1/68 , A61K48/00 , A61P35/00
摘要： Methods of inducing a CD8+ T celi response to a heterologous antigen in which at least 10% of the CD8+ T cells are
MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 pro- teins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 pro- tein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.-
5.发明公开
公开(公告)号：EP3529363A1
公开(公告)日：2019-08-28
申请号：EP17862978.8
申请日：2017-10-18
发明人： PICKER, Louis , HANSEN, Scott , FRUEH, Klaus , MALOULI, Daniel , NELSON, Jay , SACHA, Jonah , HANCOCK, Meaghan
-
公开(公告)号：EP2964769B1
公开(公告)日：2018-08-22
申请号：EP14759837.9
申请日：2014-03-05
发明人： PICKER, Louis , HANSEN, Scott , FRUEH, Klaus , MALOULI, Daniel
CPC分类号： C12N15/86 , A61K39/04 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/5256 , A61K2039/572 , C12N7/00 , C12N2710/16011 , C12N2710/16143 , C12N2740/15034
摘要： CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
-
7.发明公开CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING 审中-公开CYTOMEGALOVIRUS-VEKTOREN ZUR STEUERUNG EINES T-ZELLEN-TARGETINGS
公开(公告)号：EP2964769A1
公开(公告)日：2016-01-13
申请号：EP14759837.9
申请日：2014-03-05
发明人： PICKER, Louis , HANSEN, Scott , FRUEH, Klaus , MALOULI, Daniel
CPC分类号： C12N15/86 , A61K39/04 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/5256 , A61K2039/572 , C12N7/00 , C12N2710/16011 , C12N2710/16143 , C12N2740/15034
摘要： CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
摘要翻译： 本文公开了包含异源蛋白抗原，活性UL131蛋白（或其直系同源物），活性UL128蛋白（或其直系同源物），但其中CMV载体缺少活性UL130蛋白（或其直系同源物）的CMV载体， 。 本文还公开了包含：异源蛋白质抗原，活性UL131蛋白（或其直系同源物），活性UL130蛋白（或其直系同源物），但其中CMV载体缺少活性UL128蛋白的CMV载体。 进一步公开的是使用CMV载体产生特征为具有至少10％的CD8 + T细胞针对MHC II类所呈现的表位的免疫应答的方法。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.021 秒)
